News & Events
News & Events
Insitut Pasteur Korea selects 7 projects for its newly launched pilot program & opens its facility to the Korean academic community
2015-07-07
Pangyo, Gyeonggi, 06 July, 2015| Institut Pasteur Korea (IPK) is pleased to announce the positive response its received from its small molecule pilot screening program call, specifically made for the Korean academic research community, and enabling them to access our facility and technology platform to perform small molecule pilot screens on their own research projects. The call received 9 applications with 7 selected projects for the program.
As part of the selection process, applicants were invited to visit IPK and discuss their project with the team of screening experts. Applications, with diverse interests from antibacterial, Alzheimer's disease, to anticancer, were from multiple Korean institutions including KAIST, Yonsei University, Asan Medical Center, Sung Kyun Kwan University, Chungnam National University, Konkuk University, and POSTECH. The 7 selected projects will enter the program through an assay transfer phase followed by an assay optimization assessment phase working jointly with IPK scientists at our facility. Assays will then be miniaturized and adapted for the pilot screen in the third phase of the process. The last phase deals with large data analysis and hit identification from the pilot screens. Identified hits and their chemical structures will be given back to the collaborator for further research and characterization.
IPK launched this small molecule pilot screening program in order to give Korean researchers access to our innovative screening technology through a simple pilot program enabling them to carry out their research at our facility in Pangyo; and more importantly to interact and consult with our experts on how to develop assays, perform high throughput screening, and analyze large data. Dr. Hakim Djaballah, CEO of IPK, commented “I am glad that we can provide this opportunity to our colleagues based locally in Korea and thrilled to see a good response to our first ever pilot program. Access to the pilot screening program is free of charge to academics as we feel it is the best way to share our technology platform; and for our collaborators to generate preliminary data validating their hypotheses driven research for successful funding opportunities. We are currently working on additional pilot programs which we will be announcing soon”.
As part of the selection process, applicants were invited to visit IPK and discuss their project with the team of screening experts. Applications, with diverse interests from antibacterial, Alzheimer's disease, to anticancer, were from multiple Korean institutions including KAIST, Yonsei University, Asan Medical Center, Sung Kyun Kwan University, Chungnam National University, Konkuk University, and POSTECH. The 7 selected projects will enter the program through an assay transfer phase followed by an assay optimization assessment phase working jointly with IPK scientists at our facility. Assays will then be miniaturized and adapted for the pilot screen in the third phase of the process. The last phase deals with large data analysis and hit identification from the pilot screens. Identified hits and their chemical structures will be given back to the collaborator for further research and characterization.
IPK launched this small molecule pilot screening program in order to give Korean researchers access to our innovative screening technology through a simple pilot program enabling them to carry out their research at our facility in Pangyo; and more importantly to interact and consult with our experts on how to develop assays, perform high throughput screening, and analyze large data. Dr. Hakim Djaballah, CEO of IPK, commented “I am glad that we can provide this opportunity to our colleagues based locally in Korea and thrilled to see a good response to our first ever pilot program. Access to the pilot screening program is free of charge to academics as we feel it is the best way to share our technology platform; and for our collaborators to generate preliminary data validating their hypotheses driven research for successful funding opportunities. We are currently working on additional pilot programs which we will be announcing soon”.